The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target

Acta Oncologica

Volumn 35, Issue 4, 1996, Pages 429-434

  Picksley, Steven M ^a   Spicer, James F ^b   Barnes, Diana M ^b   Lane, David P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER; CONTROLLED STUDY; DRUG DEVELOPMENT; FAMILIAL DISEASE; FEMALE; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030036517     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609109917     Document Type: Article

References (36)

1. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancer. Science 1991; 253: 49-53.
2. Lane DP. p53 and human cancers. Br Med Bull 1994; 50: 582-99.
3. Pietenpol, JA, Tokino T, Thiagalingam S, El-Deiry W, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 1994; 91: 1998-2002.
4. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumourigenic mutations. Science 1994; 265: 346-55.
5. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
6. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. Embo J 1993; 12: 461-8.
7. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-60.
8. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-3.
9. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53: 16-8.
10. Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-4.
11. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-9.
12. Cordon CC, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794-9.
13. Otto A, Deppert W. Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene 1993; 8: 2591-603.
14. Landers JE, Haines DS, Strauss B, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overex-pression identified in human tumor cells. Oncogene 1994; 9: 2745-50.
15. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993; 13: 301-6.
16. Barnes DM, Hanby AM, Gillett CE, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992; 340: 259-63.
17. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
18. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF-1, a potential mediator of p53 tumour suppression. Cell 1994; 75: 817-25.
19. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1994; 75: 805-16.
20. Noda A, Ning Y, Venable SF,Piera-Smith OM, Smith JR. Cloning of a senescent cell-derived inhibitor of DNA sythesis using an expression screen. Exper.Cell.Res 1994; 211: 90-98.
21. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992; 101: 183-9.
22. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-44.
23. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9: 2523-9.
24. Camplejohn RS, Perry P, Hodgson SV, et al. A possible screening test for inherited p53-related defects based on the apoptotic responsee of peripheral blood lymphocytes to DNA damage. 1995; 72: 654-662.
25. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-21.
26. Birch JM, Heighway J, Teare MD, et al. Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 1994; 70: 1176-81.
27. Forus A, Florenes VA, Maelandsmo GM, et al. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ 1993; 4: 1065-70.
28. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994; 86: 1297-302.
29. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 4107-14.
30. Marston NJ, Crook T, Vousden KH. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 1994; 9: 2707-16.
31. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional actviation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994; 8. 1235-46.
32. II60. Science 1995; 267: 100-3.
33. Legros Y, Lafon C, Soussi T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 1994; 9: 2071-6.
34. Stephen CW, Helmenin P, Lane DP. characterisation of epi-topes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol 1995; 248: 58-78.
35. Lane DP Cancer. p53, guardian of the genome. Nature 1992; 358: 15-6.
36. Lowe SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 1994; 91: 2026-30.